Prof. Dr. Falk Nimmerjahn



close-button

Project Types

Third Party Funds Group - Overall project
Third Party Funds Group - Sub project
Third party funded individual grant
Internally funded project
FAU own research funding: EFI / IZKF / EAM ...
Non-FAU Project

Status

Project year

From
To
Regulierung der durch Autoantikörper ausgelösten Knochenentzündung und Osteoklastogenese durch den C-Typ-Lektin-Rezeptor Mincle (C01) (SFB TRR 369 C01) TRR 369: DIONE Entzündungsbedingte Knochendegeneration (SFB TRR 369) April 1, 2024 - Dec. 31, 2027 Einfluss zellulärer und humoraler Immunkomponenten in den initialen Phasen der RA (TP 06) PANDORA - Pathways triggering AutoimmuNity and Defining Onset of early Rheumatoid Arthritis Jan. 1, 2022 - Dec. 31, 2024 Mapping the effector response space of antibody combination Dec. 18, 2019 - Nov. 30, 2024 Consortium for Immunotherapeutics against Emerging Viral Threats May 1, 2019 - April 30, 2024 IMPACT OF a2,6-LINKED SIALIC ACID RESIDUES ON B CELL DEVELOPMENT AND ANTIBODY FUNCTION IN VIVO (TP 3) Sialinsäure als Regulator in Entwicklung und Immunität July 1, 2020 - June 30, 2023 Pathogenicity of IgA-type autoantibodies in pemphigoid disease June 1, 2020 - May 31, 2023 Projekt B2: Die IgG Glykosylierung in der Regulation der rheumatoiden Arthritis (TP 06) July 1, 2019 - June 30, 2022 Glykosylierung von IgG Subtypen Nov. 1, 2018 - Oct. 31, 2021 Understanding the role of the human inhibitory FcGamma-receptor for autoreactive and protective humoral immune responses in vivo (13) (TRR 130) TRR 130: B-Zellen: Immunität und Autoimmunität July 1, 2013 - July 1, 2016 Investigating the mechanism of antibody mediated effector functions in vivo (B14) (SFB 643) SFB 643: Strategien der zellulären Immunintervention Jan. 1, 2013 - Jan. 1, 2016